Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Emcor (EME)

EMCOR Q4 revenue up 19.7% to $4.51 billion; 2026 EPS guidance $27.25-$29.25

Positive Impact 3 of 5 earnings Written later

EMCOR reported record fourth-quarter and full-year 2025 revenue and diluted EPS, and gave 2026 guidance of $17.75 billion to $18.50 billion in revenue and $27.25 to $29.25 in diluted EPS. Fourth-quarter GAAP diluted EPS included a $144.9 million gain on the sale of its United Kingdom operations, and non-GAAP diluted EPS was $7.19. Remaining performance obligations reached a record $13.25 billion, which the company cites as support for its 2026 outlook.

Key points

  • Q4 2025 revenues were $4.51 billion, up 19.7% from $3.77 billion; organic growth was 9.5%.
  • Q4 2025 GAAP diluted EPS was $9.68 versus $6.32 a year earlier; non-GAAP diluted EPS was $7.19.
  • Full-year 2025 revenues were $16.99 billion and GAAP diluted EPS was $28.19; non-GAAP diluted EPS was $25.87.
  • 2026 guidance: revenues of $17.75 billion to $18.50 billion, operating margin of 9.0% to 9.4%, and diluted EPS of $27.25 to $29.25.

The filing

CompanyEmcor (EME)
Form8-K, current report
Filed with the SECFeb 26, 2026, 9:33 AM ET
Accession number0000105634-26-000027

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.